These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6112741)

  • 21. Normal responsivity of serum IRI following subcutaneous administration of glucagon in 25 cases of pituitary dwarfism in children and adolescents. A negative report.
    Popa M; Florea I; Simionescu L
    Folia Endocrinol; 1974 Jun; 27(3):265-71. PubMed ID: 4597341
    [No Abstract]   [Full Text] [Related]  

  • 22. [Adrenocorticotropic function of the pituitary gland in endocrine diseases].
    Slavnov VN; Epshteín EV; Malinkovich VD; Luchitskií EV; Iakovlev AA
    Probl Endokrinol (Mosk); 1976; 22(5):24-6. PubMed ID: 191803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Natural peptides and their analogs. XXXV. Synthesis and properties of [Ala5, Orn9]somatostatin].
    Shvachkin IuP; Smirnova AP; Ermak NM; Fedotov VP; Sadovnikova NV
    Bioorg Khim; 1985 Aug; 11(8):1026-36. PubMed ID: 2865960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin: physiological and clinical significance.
    Guillemin R; Gerich JE
    Annu Rev Med; 1976; 27():379-88. PubMed ID: 779605
    [No Abstract]   [Full Text] [Related]  

  • 25. [Characteristics of carbohydrate metabolic disorders and of the secretion of insulin, glucagon and somatotropin in patients with chronic glomerulonephritis and chronic kidney failure].
    Trusov VV; Kazakova IA; Nasachev AA
    Ter Arkh; 1986; 58(8):13-8. PubMed ID: 3532406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings.
    DeFronzo RA; Sherwin RS; Dillingham M; Hendler R; Tamborlane WV; Felig P
    J Clin Invest; 1978 Feb; 61(2):472-9. PubMed ID: 621284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory action of somatostatin on pancreatic alpha and beta cell function.
    Leblanc H; Anderson JR; Sigel MB; Yen SS
    J Clin Endocrinol Metab; 1975 Apr; 40(4):568-72. PubMed ID: 1092707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of gastrin in regulating insulin and glucagon secretion in patients with diabetes mellitus].
    Starosel'tseva LK; Kniazeva AP; Belovalova IM; Abduraimova GR
    Probl Endokrinol (Mosk); 1988; 34(4):20-5. PubMed ID: 3057484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of physical exercise on secretion of growth hormone, glucagon, and cortisol in obese and diabetic children.
    Garlaschi C; di Natale B; del Guercio MJ; Caccamo A; Gargantini L; Chiumello G
    Diabetes; 1975 Aug; 24(8):758-61. PubMed ID: 1158040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolated human growth hormone deficiency and related disorders.
    Rabinowitz D; Merimee TJ
    Isr J Med Sci; 1973; 9(11):1599-1657. PubMed ID: 4591562
    [No Abstract]   [Full Text] [Related]  

  • 31. Selective inhibitory effect of the analog D5-F-TrP8-D-Cys14 somatostatin on the arginine induced release of insulin, growth hormone and glucagon, in normal human beings.
    González-Bárcena D; Mendoza F; Graef A; Medina R; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1985; 16 Suppl 3():105-14. PubMed ID: 2878649
    [No Abstract]   [Full Text] [Related]  

  • 32. Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues.
    Coy DH; Meyers C; Arimura A; Schally AV; Redding TW
    Metabolism; 1978 Sep; 27(9 Suppl 1):1407-10. PubMed ID: 683009
    [No Abstract]   [Full Text] [Related]  

  • 33. [Insulin/glucagon relationship in spontaneous diabetic remission].
    Cresto JC; Sires JM; Ramos O; Abdenur JE; Basabe JC
    Medicina (B Aires); 1991; 51(3):195-203. PubMed ID: 1821901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin, insulin, and glucagon secretion from isolated perfused pancreas of obese rats.
    Seino S; Seino Y; Takemura J; Tsuda K; Kuzuya H; Ishikawa K; Shimazu T; Imura H
    Am J Physiol; 1981 Aug; 241(2):E146-50. PubMed ID: 6115583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin, basic and clinical studies. A review.
    Schally AV; Meyers CA
    Mater Med Pol; 1980; 12(1-2):28-32. PubMed ID: 6120265
    [No Abstract]   [Full Text] [Related]  

  • 36. [Changes in blood sugar, and insulin levels induced by somatostatin in normal, diabetic and acromegalic subjects].
    Carmina E; Lanzara P; Janní A
    Minerva Med; 1976 Apr; 67(18):1204-4-10. PubMed ID: 934480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of diabetes mellitus.
    Sherwin R; Felig P
    Med Clin North Am; 1978 Jul; 62(4):695-711. PubMed ID: 682722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of hyperglycemic hormones to the pathogenesis of diabetes mellitus.
    Sperling MA
    Am J Dis Child; 1977 Oct; 131(10):1145-9. PubMed ID: 910769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Somatotropic function of the hypophysis in endocrine diseases].
    Slavnov VN; Epshteĭn EV; Luchitskiĭ EV; Malinkovich VD; Markov VV
    Probl Endokrinol (Mosk); 1977; 23(6):29-35. PubMed ID: 600925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist.
    Strowski MZ; Cashen DE; Birzin ET; Yang L; Singh V; Jacks TM; Nowak KW; Rohrer SP; Patchett AA; Smith RG; Schaeffer JM
    Endocrinology; 2006 Oct; 147(10):4664-73. PubMed ID: 16857751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.